Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 2FED 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1

Interventions

Exercise 6pembrolizumab 5enzalutamide 4Docetaxel 4Colonoscopy 4Celecoxib 4sargramostim 3apalutamide 3Prednisone 3Methods 3Leuprolide 3Itraconazole 3Imiquimod 3Granulocyte-Macrophage Colony-Stimulating Factor 3Golytely 3Cryotherapy 3Abiraterone Acetate 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Yoga 2Topotecan 2Testosterone 2Tablets 2Simvastatin 2Radiosurgery 2Palliative Care 2Midazolam 2Gelatin 2Decision Support Techniques 2Collagenases 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Interventional × Picibanil × Clear all
NCT00010452 2015-03-25

Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

FDA Office of Orphan Products Development

Phase 2/3 Completed
150 enrolled

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon âš¡